FDA Approves Pfizer’s RSV Vaccine for Adults at Increased Risk The U.S. Food and Drug Administration (FDA) has taken a significant step in public health by approving Pfizer’s RSV vaccine, named Abrysvo, for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 18 to 59 who are at …
Continue reading “FDA Approves Pfizer’s Abrysvo RSV Vaccine for At-Risk Adults Aged 18-59”